by Neoteryx, on November 16,2021
November 2021 — The Mitra® microsampling device from US-based Neoteryx has been registered in Brazil as a Class 1 in vitro diagnostic (IVD) medical device by ANVISA, the Agência Nacional …
Read Storyby Neoteryx, on October 13,2021
October 2021 — The Science History Institute (the Institute) has announced Fasha Mahjoor as the recipient of the 21st annual Pittcon Heritage Award. Mahjoor is the founder and CEO of …
Read StoryThe latest product releases, company news and microsampling industry updates from Neoteryx.
If you don’t find the information & assets you need via the buttons below, please contact us here: press@neoteryx.com
Fact Sheet & FAQs
© Neoteryx 2021 | Privacy Policy | Sitemap
421 Amapola Ave
Torrance, CA 90501
This site is protected by reCAPTCHA and the Google Privacy
Policy and Terms of Service apply.
Mitra® devices are intended as a specimen collector and for the storage and transport of biological fluids. They are CE-IVD self-certified in the UK and EU, a Class 1 IVD in Australia, Brazil & China, Class B in South Africa, and registered with health agencies in Canada, Thailand, and Ukraine. In the United States, Mitra devices are for Research Use Only (RUO). In some countries, Mitra devices may be used in clinical diagnostic laboratory systems after the laboratory has validated their complete system in compliance with relevant rules and regulations. Mitra is a registered trademark of Neoteryx, LLC.
hemaPEN® is supplied for therapeutic or IVD use in Australia, New Zealand, UK, EU and USA only: ARTG number: 280007; CE mark, general IVD; US FDA number: D410490. Outside of the territories listed above, the hemaPEN is supplied for research use only (RUO) and not for therapeutic or diagnostic use. hemaPEN® is a registered trademark owned by Trajan Scientific Australia Pty Ltd.
Copyright © 2022 Neoteryx, LLC, Part of the Trajan Family. All rights reserved.